Advertisement

Topics

Search Results for "Sjogren A Belimumab"

16:59 EDT 23rd October 2017 | BioPortfolio

Matching Channels

None

Matching News

EU Regulators Approve Self-injectable Belimumab for Lupus

The new version of belimumab can spare patients with systemic lupus erythematosus the need to have an intravenous infusion of the drug at a hospital or clinic. International Approvals

Belimumab (Benlysta) Cleared in Japan for Lupus

Belimumab is now approved in Japan for the treatment of adults with active, autoantibody-positive systemic lupus erythematosus who do not respond adequately to existing therapies. International Appr...

US of Salivary Glands May Have Role in Diagnosing Sjogren's

Ultrasonography of the major salivary glands may have a role in the diagnostic evaluation of patients with clinically suspected primary Sjogren's syndrome, researchers from the Netherlands report. R...

Sjogren's Syndrome Market Insights, Epidemiology and Market Forecast2023 [Updated: 30052017] Prices from USD $4208

DelveInsight's Sjogren's Syndrome Market Insights, Epidemiology and Market Forecast2023 Reports provides an overview of the disease and global market trends of the Sjogren's Syndrome for the seven ma...

Belimumab plus standard lupus therapy seen as safe, effective over 10 years

MADRID — Belimumab plus standard therapy was safe and effective over 10 years in patients with lupus, according to findings presented at the EULAR Annual Congress. “In lupus, the underlying diseas...

Role of Novel Hepatitis Delta Virus Variant in Sjogren’s Syndrome

Sjögren’s is a chronic autoimmune disease characterized by dry mouth and eyes, fatigue, and musculoskeletal pain resulting from the attack of the moisture-producing glands by the body’s own white...

AAV Mediated CTLA-4 Gene Transfer to Treat Sjogren's Syndrome

Sjögren’s syndrome is an autoimmune disease that affects over 2 million Americans, primarily over the age of 40. One of the major outcomes of Sjögren's syndrome is xerostomia (dry mouth) that is ...

FDA Clears Self-injectable Belimumab (Benlysta) for SLE

FDA Approvals

Matching PubMed Articles

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.

Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimu...

Impact of Sjogren's syndrome on Parkinson's disease: A nationwide case-control study.

To investigate whether Sjogren's syndrome would have an influence on the development of Parkinson's disease.

OPHTHALMIC FINDINGS IN LATE STAGE SJOGREN-LARSSON SYNDROME.

To report spectral domain optical coherence tomography and fundus autofluorescence documentation of late stage macular findings associated with Sjogren-Larsson Syndrome in three adult siblings.

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.

Intravenous belimumab 10 mg/kg every 4 weeks is indicated in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard systemic lupus erythematosus care. Subcutaneo...

Adult-onset hypophosphatemic osteomalacia associated with Sjogren syndrome: Clinical case report.

Hypophosphatemic osteomalacia (HO) is a metabolic bone disease, exhibiting different etiologies such as genetic mutation, tumor induction, dysimmunity, or renal disease. Sjogren's syndrome (SS) is a c...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement